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Introduction 27
Antibiotic resistance is an urgent threat to human health and requires urgent actions from 28 physicians, patients, industries, governmental agencies and the academic community worldwide. 29 According to the last document from the Centers for Disease Control and Prevention (CDC) 30 regarding antibiotic resistance in the United States, from 2013, the number of people with serious 31 infections caused by resistant bacteria reaches two million every year, with at least 23,000 deaths per 32
year directly caused by these infections (1). The situation is similarly warning in Europe, where 33 25,100 deaths were reported from the European Centre for Disease Prevention and Control in 2007 34
(2). Globally, 700,000 deaths are estimated every year as a consequence of antibiotic resistance (3) . 35 The same CDC document lists four general action lines to address antibiotic resistance: (i) preventing 36
infections and the spread of resistance; (ii) tracking resistant bacteria; (iii) improving the use of 37 current antibiotics; (iv) developing of new antibiotics (1). 38
Since bacteria have a short doubling time and efficient mechanisms for plasmid sharing, the 39 development of antibiotic resistance is a very efficient defense mechanism. So, as previously said by 40 Walsh and Wencewicz, the development of resistance is not a matter of if, but rather a matter of when 41
(4) and, despite the title of this paper (which is rather provocative), there is no way we can escape 42 from it (5). On the contrary, the development/discovery of new antibiotics will tend to be a 43 continuous goal to be achieved in drug discovery pipelines. 44
Interestingly, even after what has been named as the 'golden age' of antibiotics development, 45 the drugs currently in the market are restricted to only five molecular targets and/or pathways (4): (i) 46 the peptidoglycan/cell wall biosynthesis, site of action of beta-lactam antibiotics, for example; (ii) the 47 protein biosynthesis, where the ribosome is an important target; (iii) DNA replication and RNA 48 transcription; (iv) the folate biosynthesis pathway, and (v) the disruption of the bacterial membrane. 49 Given the relevance of the antibiotic therapy and the emergence of antibiotic resistance, the available 50 choices of current drugs are very narrow in the context of the mechanism of action restricted to only 51 five molecular/pathway targets. 52
Antibiotic resistance, as a threat to human health, should be addressed in multiple, and 53 simultaneous ways. For academia, an interesting way to address antibiotic resistance is the discovery 54 and validation of new targets/pathways that could be specifically targeted by new antibiotic 55 candidates. It is worthy of note that, according to Kelly and Davies (3) , no new class of antibiotics 56 was discovered and released for routine treatment since the 1980s, highlighting the outstanding role 57 that academia can have in the preliminary research for discovery and validation of druggable 58 targets/pathways. 59 About 7% of the E. coli genome, 303 genes, were shown to be composed of essential genes 60 (5,6). Under stress conditions caused by a limited medium, additional 119 genes show some 61 condition-dependent essentiality, including several genes related to the metabolism and synthesis of 62 essential molecules such as amino acids, and nucleotides (5) and, obviously, some of these 63 targets/pathways can be an interesting choices for the development of new antibiotic candidates. A 64 promising approach to screen compounds for their activity in metabolic pathways was shown by 65
Zlitni and coworkers (7). The authors searched for antibacterial compounds under poor nutrient 66 media and found three potential compounds in this screening strategy (7). Worth of note, the 67 metabolic profile of existing antibiotics showed that the supplementation of vitamins B5, B6, B1, and 68 B2 did not significantly reverse the antimicrobial effect of any of the 24 inhibitors assayed (7), 69
suggesting that the current antibiotics do not explore these essential pathways. 70
In this context, the enzymatic routes for the biosynthesis of vitamins are very interesting 71 pathways to be explored as potential targets for the discovery of new antibiotic candidates. Vitamin  72  B1, for example, cannot be synthesized by humans, although several microorganisms can synthesize  73 this vitamin, including pathogens. In the absence of thiamin (vitamin B1), the activity of several 74 carbohydrate metabolism enzymes is impaired, including pyruvate dehydrogenase, which connects 75 glycolysis and the citric acid cycle (8). Other thiamin dependent enzymes are transketolase, α-76 ketoacid decarboxylase, α-ketoacid dehydrogenase and acetolactate synthase (9). A very similar 77 scenario was observed for pyridoxal 5'-phosphate (vitamin B6) in the model Gram-positive organism 78
Bacillus subtilis (10). 79
The pathways involved in the synthesis of vitamins, in particular, vitamin B1 (thiamin) and 80 B6 (pyridoxal), seem to be of great relevance, since they are involved in central processes in the 81 metabolism of carbohydrates and amino acids and the corresponding enzymes are found in most 82 bacteria, fungi and plants but not in humans (8) The analyses provided here are the result of the interrogation of the enzymes in the 96 biosynthesis pathways for thiamin and pyridoxine phosphate or pyridoxal phosphate using the KEGG 97 database (14, 15) . For this purpose, the KEGG pathway for thiamin metabolism (map 00730) was 98 listed for the ESKAPE pathogens using, whenever possible, commercial strains rather than specific 99 or antibiotic-resistant strains. Briefly, for each pathogen (Enterococcus faecium, Staphylococcus 100 aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and 101
Enterobacter) a KEGG search for the maps of thiamin and pyridoxal metabolism was done, looking 102
for the existing genes in commercial strains for each of the ESKAPE organisms. For the sake of 103 comparison, some additional resistant strains were listed, with no differences in the observed genes 104
for the pathways under study. A similar search was carried out for the vitamin B6 metabolism (map 105 00750) in KEGG, interrogating the existing enzymes for the ESKAPE pathogens in comparison with 106 humans. The analysis was focused in the enzymes in the biosynthesis of B1 and B6 vitamin in an 107 attempt to identify the most promising targets for future medicinal chemistry studies. Finally, a table  108 listing the existing genes for each pathogen was compiled and is presented in the following sections. 109
Using the existing literature, we sought to identify whenever possible the cases of enzymes 110 with functional redundancy with another enzyme for the same organism. The identified cases were 111 discussed as less promising targets for medicinal chemistry campaigns. Additionally, the existing data for enzyme inhibition using natural or synthetic compounds was compiled to provide initial 113 proof-of-concept clues about the druggability of the identified promising targets. 114
When necessary, the sequence of an enzyme of the pathway was used to search for homologues using 115 BLAST (16) searches against the PDB (17) or the non-redundant database of proteins using BLAST 116 default parameters, i.e., minimum expected threshold of 10, a word size of 6 and the BLOSUM62 117 substitution matrix. 118 119 3
Results and Discussion 120
Thiamin Biosynthesis 121
The biosynthesis pathway for thiamin involves two branches, as shown in Figure 1 . In 122 summary, thiamin is synthesized from 4-amino-5-hydroxymethyl-2-methylpyrimidine (HMP, 123 superior branch in Figure 1 ) and 5-(2-hydroxyethyl)-4-methylthiazole (THZ, inferior branch can be further phosphorylated by ThiD (9). 162
In the other branch of the thiamin biosynthesis pathway, thiazole phosphate can be generated 163 from thiazole alcohol incorporated from the medium and phosphorylated by ThiM or it can be 164 synthesized in a series of enzymatically catalyzed reactions using amino acids such as glycine or 165 tyrosine as substrates (9). In this context, according to Begley and coworkers (9), lesions in the ThiM 166
gene were observed to be prototrophic. In contrast, selective mutations of ThiD and ThiE led to the 167 requirement of externally provided thiamin (9). 168
ThiE is central to the pathway since the enzyme merges the two branches to finally synthesize 169 thiamin phosphate (Figure 1 ). It is important to highlight that many of the mutational analysis was 170 carried out in E. coli and, as level, Nodwell and coworkers showed that Listeria monocytogenes, which is known to uptake 217 thiamine from the environment, is still sensible to Rugulactone and its derivatives Ru1 and Ru2 (25). 218
When grown in a chemical defined media without thiamine, the inhibitory effects of Rugulactone are 219 potentiated with a 4-fold reduction in the MIC (25). However, the inhibitory effect observed even in 220 the presence of thiamine highlight that the blockade of the de novo biosynthesis pathway is still a 221 promising strategy. As a third level, the natural compound bacimethrin, isolated from Bacillus 222 megaterium and from Streptomyces albus is known to be toxic for bacteria with MIC at low 223 micromolar range (33,34). The mechanism of action of bacimethrin is based on the formation of 2'-224 methoxy-thiamine where bacimethrin is used by ThiD instead of HMP. 2'-methoxy-thiamine 225 pyrophosphate inhibits E. coli growth at concentrations 15 times lower than bacimethrin (35). 226
Interestingly, some Salmonella enterica thiD mutants were shown to be bacimethrin resistant (36). 227
Together, these data suggest that a very promising approach can be devised by the design of suicide 228 drugs, i.e., compounds that are recognized by the enzymes in the pathway but lead to final 229 compounds that can't be used as thiamine substituents. Bacimethrin is a good example of a suicide 230 inhibitor and, although its effects can be reverted by increased thiamine concentrations, the vitamin 231 concentration that pathogens are exposed are usually defined within a narrow range. 232 233
Pyridoxal Biosynthesis 234
Pyridoxal, pyridoxine and pyridoxamine, together with their respective phosphate esters 236 compose the six vitamers for vitamin B6 and can be interconverted (37). There are two biosynthetic 237 routes for pyridoxal 5'-phosphate: a deoxyxylulose 5-phosphate-dependent pathway found in some 238 bacteria and a deoxyxylulose 5-phosphate-independent pathway found in all kingdoms (37,38). This 239 second and widespread pathway, curiously, depends on only two enzymes, as shown in Figure 2 . 240
In this pathway, the enzyme Pdx2 converts L-glutamine into L-glutamate and an ammonium 241 molecule. The latter is thought to diffuse to Pdx1 active site, which also uses glyceraldehyde 3-242 phosphate and D-ribose 5-phosphate to synthesize pyridoxal 5'-phosphate (37,39). Interestingly, to 243
properly synthesize pyridoxal 5'-phosphate, a complex involving twelve Pdx1 molecules and twelve 244
Pdx2 molecules has to be assembled (40-42) and this assembly is further stabilized by the interaction 245 with L-glutamine (43). 246
Similar to what is observed to the thiamine biosynthesis pathway, humans lack the genes for 247
Pdx1 and Pdx2, making the development of specific antibiotic candidates an attracting strategy. In 248 the same direction, for some pathogenic organisms such as Helicobacter pylori (44), Mycobacterium 249 tuberculosis (45), and Streptococcus pneumoniae (46), the depletion in vitamin B6 resulted in 250 reduced virulence, indicating that the biosynthesis of this vitamin may be a good strategy for the 251 design of new antibiotic candidates. 252
Very interestingly and in contrast to what was observed for the thiamine pathways, from the 253 ESKAPE pathogens, S. aureus is the only microorganism that has the ribose 5-phosphate dependent 254 pathway for the biosynthesis of pyridoxal 5'-phosphate, as shown in Table 2 . A single enzyme (Pdx1 255 or Pdx2 alone) is never observed for these organisms ( Using a structural homology model, Reeksting and coworkers identified some ribose 5'-277 phosphate analogues with interesting in vitro inhibitory effects on the enzyme Pdx1 from P. 278 falciparum (12). The compounds were identified in a structure-based computational screening 279 campaign and were shown to have inhibitory effects in vivo, as well as the in vitro effect. The authors 280 also showed that the in vivo effects could be at least partially suppressed in a mutant strain 281 overexpressing Pdx1 and Pdx2, in a clear indication that the effect of the analogues was due their 282 inhibition of the pyridoxal 5'-phosphate biosynthesis pathway (12). 283
The inhibition of the Pdx2 activity by the glutamine analogue acivicin was also demonstrated 284
to be a feasible strategy for the inhibition of the vitamin B6 biosynthesis pathway (52) . Raschle and 285 coworkers showed that when inhibited by acivicin, Pdx2 is incapable of interacting with Pdx1, thus 286 disrupting the pyridoxal 5'-phosphate synthase activity. Interestingly, acivicin is a covalent inhibitor, 287 that binds to a cysteine residue. So, it seems that multiple strategies may be available for the design 288
of new binders, including the inhibition of Pdx2 (covalent and non-covalent), the inhibition of Pdx1 289
and possibly the inhibition of the assembly of the 24-mer complex with Pdx1/Pdx2. Another 290 possibility to address the inhibition of PLP biosynthesis might be at the level of the Pdx1 291 transcription, which was shown to be regulated by PdxR (46). In principle, if PdxR action could be 292 regulated by an exogenous chemical probe, the PLP synthase activity would be regulated as well. 293
However, a proof-of-concept experimental validation is still necessary. 294
Finally, a salvage pathway for vitamin B6 is found in many bacteria, as well as in humans. In 295 E. coli, it involves two enzymes: PdxK and PdxY. These kinases act phosphorylating the vitamers 296 pyridoxal, pyridoxine and pyridoxamine into their phosphorylated forms (23,37,53). Interestingly, in 297 some organisms, including pathogenic microorganisms such as S. aureus, the PdxK activity is carried 298 out by the HMP kinase ThiD, showing some functional convergence between the vitamin B6 and B1 299 pathways (24). Not surprisingly, this enzyme has also been shown to be validated druggable target 300
for some pathogens, such as Trypanosoma brucei for example (13), although specificity may be an 301 important issue, since humans also have genes for PdxK known to be inhibited by drugs like 302 theophylline, for example, with known neurotoxic effects (54). 303
Again, the same question asked for the thiamine biosynthesis pathway can be asked here: how 304
can the microbial uptake of vitamin B6 overcome the blockade of the biosynthetic pathway? Some 305 evidences suggest that the blockade might be effective. For example, in S. pneumoniae, the deletion 306 of Pdx1 resulted in defective growth of the bacteria. The growth was shown to be restored under 307 increased concentrations of vitamin B6 (46). A similar scenario was also observed for M. 308 tuberculosis (45), suggesting that the uptake might not be enough to meet the pathogen's requirement 309 of the vitamin. 310
In conclusion, the biosynthesis pathways for vitamin B1 (thiamine) and B6 (pyridoxal 5'-311 phosphate) may be interesting molecular targets for the development of new chemical probes aiming 312 to inhibit the synthesis of these essential cofactors in pathogenic organisms. Model compounds, 313 mainly based on substrate analogues showed that inhibition of the vitamin B1 biosynthetic enzymes, 314
ThiD and ThiE, as well as Pdx1, Pdx2 and PdxK in pyridoxal 5'-phosphate biosynthesis pathway 315 have shown an initial proof of concept for the model and it is up the scientific community and/or 316 researcher in industry to explore these target further. 317
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